Abstract:We read the study by Durila et al 1 Durila M, Vajter J, Garaj M, et al. Acquired primary hemostasis pathology detected by platelet function analyzer 200 seen during extracorporeal membrane oxygenation is sufficient to prevent circuit thrombosis: a pilot study. J Heart Lung Transplant. 2020;39:980-982. Google Scholar with interest; however, we seek several clarifications. First, a separate study by Yu et al 2 Yu ES, Jeon MJ, Kang KW, et al. The role of platelet function analyzer-200 in predicting perioperative bleeding risk [e-pub ahead of print]. Korean J Intern Med. doi:10.3904/kjim.2019.112, accessed September 9, 2020. Google Scholar showed that the results of platelet function analyzer 200 (PFA 200) are influenced by various factors, such as the use of aspirin and other non-steroidal anti-inflammatory agents, blood group type, hematocrit and time of blood collection, transfusions, and underlying diseases. The severity of surgery might cause bleeding, which affects collagen–epinephrine and collagen–adenosine diphosphate. The conclusion that the pathology of primary hemostasis detected by the PFA 200 (collagen–epinephrine and collagen–adenosine diphosphate) was specific for the extracorporeal membrane oxygenation (ECMO) phase of surgery is not robust and is subject to confounding bias. 3 Zhang Z Model building strategy for logistic regression: purposeful selection. Ann Transl Med. 2016; 4: 111 Crossref PubMed Scopus (192) Google Scholar Second, a continuous intravenous infusion of low-molecular-weight heparin was used to prevent venous thromboprophylaxis, but without dose described. Piwowarczyk et al 4 Piwowarczyk P, Borys M, Kutnik P, et al. Unfractionated heparin versus subcutaneous nadroparin in adults supported with venovenous extracorporeal membrane oxygenation: a retrospective, multicenter study [e-pub ahead of print]. ASAIO J. doi:10.1097/MAT.0000000000001166, accessed September 9, 2020. Google Scholar compared nadroparin with unfractionated heparin during veno-venous ECMO and found no significant difference in the number of thrombotic and hemorrhagic events. In the paper by Durila et al, 1 Durila M, Vajter J, Garaj M, et al. Acquired primary hemostasis pathology detected by platelet function analyzer 200 seen during extracorporeal membrane oxygenation is sufficient to prevent circuit thrombosis: a pilot study. J Heart Lung Transplant. 2020;39:980-982. Google Scholar even with the use of continuous intravenous infusion of low-molecular-weight heparin, 2 patients suffered thrombotic events. Third, the duration of the ECMO in their work is short (5 ± 3 days). The effect of duration of support on outcomes was not provided because we would suggest that the risk of thrombotic events is lower with a shorter duration of ECMO support. Given these considerations, it is difficult for us to completely agree with the conclusion that the PFA 200 analyzer may be used to prevent circuit thrombosis instead of using unfractionated heparin in patients on prolonged ECMO. We believe that a point-of-care test such as the PFA 200 may assist in adjusting anti-coagulant strategy to potentially reduce the use of unfractionated heparin rather than to prevent circuit thrombosis and obviate the use of unfractionated heparin altogether, especially in patients on prolonged ECMO support.

Incidence, clinical features, and risk factors of hemocoagulase-induced hypofibrinogenemia: A retrospective real-world study

Hemocoagulase Agkistrodon Can Prevent Bleeding and Induce Hypofibrinogenemia in Hepatic Disease Cases

A clinical study of high-dose urokinase for the treatment of the patients with hypertension induced ventricular hemorrhage

Early Fibrinogen Depletion and Symptomatic Intracranial Hemorrhage after Reperfusion Therapy.

Snake Venom Hydrogels as a Rapid Hemostatic Agent for Uncontrolled Bleeding

Hypofibrinogenemia Caused by Hemocoagulase after Colon Polyps Excision

Inverse Relationship of Bleeding Risk with Clot Burden During Pulmonary Embolism Treatment with LMW Heparin.

Efficacy and safety of hemocoagulase Agkistrodon injection for intraoperative hemostasis:a systematic review and Meta-analysis

Effect of bydroxyethyl starch with different degrees of substitution on expression of platelet membrane glycoprotein

A Multicenter, Phase III Trial of Hemocoagulase Agkistrodon: Hemostasis, Coagulation, and Safety in Patients Undergoing Abdominal Surgery.

Hemostasis During Extracorporeal Membrane Oxygenation: More Questions

Hemorrhagic fibrino(geno)lytic enzymes from snake venom

Transient blood thinning during extracorporeal blood purification via the inactivation of coagulation factors by hydrogel microspheres

Bioactive hydrogels with pro‐coagulation effect for hemostasis

Structural characterization of a clinically described heparin-like substance in plasma causing bleeding

401 Detecting Hypofibrinolysis in Clinical Coagulation Testing

Safety of Fibrinogen Concentrate for Correcting Perioperative Bleeding-Associated Hypofibrinogenemia in Adults: A Single-Center Experience

Uncommon defibrinogenation and coagulopathy caused by Trimeresurus stejnegeri stejnegeri envenomation in a patient with swelling above the ankle

A Cysteine Enzyme Hemostat for Efficient Heparin-Tolerant Blood Coagulation

Handheld point-of-care devices for snakebite coagulopathy: a scoping review

Reply: Intravenous Hyaluronidase with Urokinase As Treatment for Arterial Hyaluronic Acid Embolism